Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been historic in terms of the number of lives tragically affected and the huge toll of morbidity and mortality.1 During the pandemic’s first year there were many drugs employed and formally studied, with at best modest clinical benefits.2 In mid-2021, results of studies with 2 new drugs brought substantial new hope. Merck and Ridgeback Biotherapeutics’ drug, molnupiravir, was reported to reduce death and hospitalization from coronavirus disease 2019 (COVID-19) by 30%.